Evidence map›Paper›PMID 32757093›Full record

ReviewJournal of neuro-oncology2021

Nanoparticles as immunomodulators and translational agents in brain tumors.

Adam J Grippin, Kyle A Dyson, Sadeem Qdaisat, James McGuiness, Brandon Wummer, Duane A Mitchell, Hector R Mendez-Gomez, Elias J Sayour

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of neuro-oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Adam J GrippinUF Brain Tumor Immunotherapy Program, Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, 1149 South Newell Drive, Gainesville, FL, 32611, USA.
Kyle A DysonUF Brain Tumor Immunotherapy Program, Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, 1149 South Newell Drive, Gainesville, FL, 32611, USA.
Sadeem QdaisatUF Brain Tumor Immunotherapy Program, Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, 1149 South Newell Drive, Gainesville, FL, 32611, USA.
James McGuinessUF Brain Tumor Immunotherapy Program, Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, 1149 South Newell Drive, Gainesville, FL, 32611, USA.
Brandon WummerUF Brain Tumor Immunotherapy Program, Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, 1149 South Newell Drive, Gainesville, FL, 32611, USA.
Duane A MitchellUF Brain Tumor Immunotherapy Program, Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, 1149 South Newell Drive, Gainesville, FL, 32611, USA.
Hector R Mendez-GomezUF Brain Tumor Immunotherapy Program, Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, 1149 South Newell Drive, Gainesville, FL, 32611, USA.
Elias J SayourUF Brain Tumor Immunotherapy Program, Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, 1149 South Newell Drive, Gainesville, FL, 32611, USA. elias.sayour@neurosurgery.ufl.edu.ORCID http://orcid.org/0000-0002-5309-3197
Allen Institute for Brain Science · US

Funding

Efficacy of Dendritic Cell Vaccines Targeting CMV in Glioblastoma (phase 2 DC vaccine)R01CA175517 · NCI · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A., SAMPSON, JOHN H. · 2015 to 2020
$3.1M
Enhancing Adoptive Immunotherapy Targeting Pediatric High-Grade GliomasR01CA195563 · NCI · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A., PACKER, ROGER · 2015 to 2019
$2.8M
Harnessing the Immunologic Capacity of RNA-nanoparticle Vaccines Targeting GlioblastomaK08CA199224 · NCI · UNIVERSITY OF FLORIDA · PI SAYOUR, ELIAS · 2016 to 2020
$791k
Immunologic Targeting of Developmentally-Regulated Antigens for the Treatment of High-Risk MedulloblastomaF30CA221345 · NCI · UNIVERSITY OF FLORIDA · PI DYSON, KYLE · 2017 to 2021
$207k
Engineering RNA-nanoparticles to enhance dendritic cell mediated treatment of glioblastomaF30CA228280 · NCI · UNIVERSITY OF FLORIDA · PI GRIPPIN, ADAM · 2018 to 2020
$140k
NCI NIH HHS F30 CA221345NCI NIH HHS F30 CA228280NCI NIH HHS K08 CA199224NCI NIH HHS R01 CA175517NCI NIH HHS R01 CA195563NIH HHS F30CA221345NIH HHS F30-CA228280NIH HHS K08CA199224NIH HHS R01-CA175517NIH HHS R01-CA195563
6 · The paper itself

Abstract

introductionBrain tumors remain especially challenging to treat due to the presence of the blood-brain barrier. The unique biophysical properties of nanomaterials enable access to the tumor environment with minimally invasive injection methods such as intranasal and systemic delivery.

methodsIn this review, we will discuss approaches taken in NP delivery to brain tumors in preclinical neuro-oncology studies and ongoing clinical studies.

resultsDespite recent development of many promising nanoparticle systems to modulate immunologic function in the preclinical realm, clinical work with nanoparticles in malignant brain tumors has largely focused on imaging, chemotherapy, thermotherapy and radiation.

conclusionReview of early preclinical studies and clinical trials provides foundational safety, feasibility and toxicology data that can usher a new wave of nanotherapeutics in application of immunotherapy and translational oncology for patients with brain tumors.

Indexed as

Brain NeoplasmsNanoparticlesAdjuvants, ImmunologicBlood-Brain BarrierDrug Delivery SystemsHumansImmunologic FactorsAdjuvants, ImmunologicImmunologic FactorsBiomodulationClinical trialsImmunotherapyNanoparticles

Identifiers

PMID32757093
PMCPMC11262791
OpenAlexW3047304350

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.